NO302065B1 - Fremgangsmåte til fremstilling av en anordning for transdermal avgivelse av et aktivt middel - Google Patents
Fremgangsmåte til fremstilling av en anordning for transdermal avgivelse av et aktivt middel Download PDFInfo
- Publication number
- NO302065B1 NO302065B1 NO905270A NO905270A NO302065B1 NO 302065 B1 NO302065 B1 NO 302065B1 NO 905270 A NO905270 A NO 905270A NO 905270 A NO905270 A NO 905270A NO 302065 B1 NO302065 B1 NO 302065B1
- Authority
- NO
- Norway
- Prior art keywords
- reservoir
- active agent
- agent
- adhesive layer
- nicotine
- Prior art date
Links
- 239000013543 active substance Substances 0.000 title claims description 101
- 230000037317 transdermal delivery Effects 0.000 title claims description 20
- 238000004519 manufacturing process Methods 0.000 title claims description 5
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims abstract description 46
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims abstract description 45
- 229960002715 nicotine Drugs 0.000 claims abstract description 45
- 239000012528 membrane Substances 0.000 claims abstract description 40
- 230000001070 adhesive effect Effects 0.000 claims abstract description 36
- 230000000694 effects Effects 0.000 claims abstract description 36
- 239000000853 adhesive Substances 0.000 claims abstract description 33
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 26
- 239000007788 liquid Substances 0.000 claims abstract description 5
- 230000036760 body temperature Effects 0.000 claims abstract description 3
- 239000012790 adhesive layer Substances 0.000 claims description 35
- 239000002904 solvent Substances 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 9
- 150000001412 amines Chemical class 0.000 claims description 7
- 239000013464 silicone adhesive Substances 0.000 claims description 5
- 230000009467 reduction Effects 0.000 claims description 4
- 229920002367 Polyisobutene Polymers 0.000 claims description 3
- 230000009931 harmful effect Effects 0.000 claims description 3
- 239000002480 mineral oil Substances 0.000 claims description 3
- 235000010446 mineral oil Nutrition 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 239000005038 ethylene vinyl acetate Substances 0.000 claims description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 9
- GIJXKZJWITVLHI-UHFFFAOYSA-N 3-(diphenylmethyl)oxy-8-methyl-8-azabicyclo[3.2.1]octane Chemical compound CN1C(C2)CCC1CC2OC(C=1C=CC=CC=1)C1=CC=CC=C1 GIJXKZJWITVLHI-UHFFFAOYSA-N 0.000 abstract description 8
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 abstract description 4
- HJJPJSXJAXAIPN-UHFFFAOYSA-N arecoline Chemical compound COC(=O)C1=CCCN(C)C1 HJJPJSXJAXAIPN-UHFFFAOYSA-N 0.000 abstract description 4
- 230000003247 decreasing effect Effects 0.000 abstract description 4
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 abstract description 4
- ARIWANIATODDMH-AWEZNQCLSA-N 1-lauroyl-sn-glycerol Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)CO ARIWANIATODDMH-AWEZNQCLSA-N 0.000 abstract description 2
- ARIWANIATODDMH-UHFFFAOYSA-N Lauric acid monoglyceride Natural products CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 abstract description 2
- 239000002202 Polyethylene glycol Substances 0.000 abstract description 2
- 229920001223 polyethylene glycol Polymers 0.000 abstract description 2
- WAVYHSURRZBQKO-UHFFFAOYSA-N 1-cyclohexyl-4-[ethyl-[1-(4-methoxyphenyl)propan-2-yl]amino]butan-1-one Chemical compound C=1C=C(OC)C=CC=1CC(C)N(CC)CCCC(=O)C1CCCCC1 WAVYHSURRZBQKO-UHFFFAOYSA-N 0.000 abstract 1
- 229950004117 secoverine Drugs 0.000 abstract 1
- 210000004379 membrane Anatomy 0.000 description 37
- 239000010410 layer Substances 0.000 description 31
- 230000004907 flux Effects 0.000 description 21
- 229940079593 drug Drugs 0.000 description 19
- 239000003814 drug Substances 0.000 description 19
- 238000000338 in vitro Methods 0.000 description 17
- 229920001684 low density polyethylene Polymers 0.000 description 9
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 8
- 239000004702 low-density polyethylene Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- 239000004821 Contact adhesive Substances 0.000 description 6
- 230000001276 controlling effect Effects 0.000 description 6
- 230000035699 permeability Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 4
- 230000001052 transient effect Effects 0.000 description 4
- -1 PGML Substances 0.000 description 3
- GIJXKZJWITVLHI-PMOLBWCYSA-N benzatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(C=1C=CC=CC=1)C1=CC=CC=C1 GIJXKZJWITVLHI-PMOLBWCYSA-N 0.000 description 3
- 229960001081 benzatropine Drugs 0.000 description 3
- 239000000812 cholinergic antagonist Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 238000007654 immersion Methods 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 241000282412 Homo Species 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 206010040914 Skin reaction Diseases 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000002921 anti-spasmodic effect Effects 0.000 description 2
- 229920001903 high density polyethylene Polymers 0.000 description 2
- 239000004700 high-density polyethylene Substances 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000037311 normal skin Effects 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920006254 polymer film Polymers 0.000 description 2
- 230000035483 skin reaction Effects 0.000 description 2
- 231100000430 skin reaction Toxicity 0.000 description 2
- 230000005586 smoking cessation Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 238000012935 Averaging Methods 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229940124339 anthelmintic agent Drugs 0.000 description 1
- 239000000921 anthelmintic agent Substances 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 229940087730 nicorette Drugs 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229920003051 synthetic elastomer Polymers 0.000 description 1
- 239000005061 synthetic rubber Substances 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Materials Engineering (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20654688A | 1988-06-14 | 1988-06-14 | |
| US28428388A | 1988-12-14 | 1988-12-14 | |
| PCT/US1989/002561 WO1989012470A1 (en) | 1988-06-14 | 1989-06-13 | Subsaturated transdermal delivery device |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO905270D0 NO905270D0 (no) | 1990-12-06 |
| NO905270L NO905270L (no) | 1990-12-11 |
| NO302065B1 true NO302065B1 (no) | 1998-01-19 |
Family
ID=26901444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO905270A NO302065B1 (no) | 1988-06-14 | 1990-12-06 | Fremgangsmåte til fremstilling av en anordning for transdermal avgivelse av et aktivt middel |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP0427741B1 (ko) |
| JP (1) | JP2933337B2 (ko) |
| KR (1) | KR970010059B1 (ko) |
| AT (1) | ATE161734T1 (ko) |
| AU (1) | AU630614B2 (ko) |
| CA (1) | CA1338700C (ko) |
| DE (1) | DE68928533T2 (ko) |
| DK (1) | DK175805B1 (ko) |
| FI (1) | FI104700B (ko) |
| IE (1) | IE81102B1 (ko) |
| NO (1) | NO302065B1 (ko) |
| NZ (1) | NZ229515A (ko) |
| PT (1) | PT90820B (ko) |
| WO (1) | WO1989012470A1 (ko) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4943435A (en) * | 1987-10-05 | 1990-07-24 | Pharmetrix Corporation | Prolonged activity nicotine patch |
| AU682813B2 (en) * | 1988-06-14 | 1997-10-23 | Alza Corporation | Subsaturated transdermal delivery device |
| US5152997A (en) * | 1990-12-11 | 1992-10-06 | Theratech, Inc. | Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels |
| AU5354994A (en) * | 1992-10-15 | 1994-05-09 | Alza Corporation | Delayed onset transdermal delivery device |
| US6316023B1 (en) * | 1998-01-12 | 2001-11-13 | Novartis Ag | TTS containing an antioxidant |
| US8252319B2 (en) | 2004-10-21 | 2012-08-28 | Durect Corporation | Transdermal delivery system for sufentanil |
| PL1814531T3 (pl) | 2004-10-21 | 2010-11-30 | Durect Corp | Transdermalne systemy dostarczania |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4379454A (en) * | 1981-02-17 | 1983-04-12 | Alza Corporation | Dosage for coadministering drug and percutaneous absorption enhancer |
| US4704282A (en) * | 1984-06-29 | 1987-11-03 | Alza Corporation | Transdermal therapeutic system having improved delivery characteristics |
| DE3743947A1 (de) * | 1987-09-01 | 1989-03-09 | Lohmann Gmbh & Co Kg | Vorrichtung zur gesteuerten abgabe von nicotin, verfahren zu ihrer herstellung sowie ihre verwendung |
-
1989
- 1989-06-12 PT PT90820A patent/PT90820B/pt not_active IP Right Cessation
- 1989-06-13 AT AT89907896T patent/ATE161734T1/de not_active IP Right Cessation
- 1989-06-13 IE IE189489A patent/IE81102B1/en not_active IP Right Cessation
- 1989-06-13 NZ NZ229515A patent/NZ229515A/xx unknown
- 1989-06-13 EP EP89907896A patent/EP0427741B1/en not_active Revoked
- 1989-06-13 DE DE68928533T patent/DE68928533T2/de not_active Revoked
- 1989-06-13 JP JP1507345A patent/JP2933337B2/ja not_active Expired - Lifetime
- 1989-06-13 WO PCT/US1989/002561 patent/WO1989012470A1/en active IP Right Grant
- 1989-06-13 AU AU38521/89A patent/AU630614B2/en not_active Expired
- 1989-06-13 CA CA000602649A patent/CA1338700C/en not_active Expired - Lifetime
- 1989-06-13 KR KR1019900700153A patent/KR970010059B1/ko not_active IP Right Cessation
-
1990
- 1990-12-06 NO NO905270A patent/NO302065B1/no not_active IP Right Cessation
- 1990-12-13 FI FI906155A patent/FI104700B/fi active IP Right Grant
- 1990-12-14 DK DK199002976A patent/DK175805B1/da not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DK297690A (da) | 1990-12-14 |
| IE891894L (en) | 1989-12-14 |
| IE81102B1 (en) | 2000-03-08 |
| EP0427741A1 (en) | 1991-05-22 |
| JPH04500322A (ja) | 1992-01-23 |
| NO905270L (no) | 1990-12-11 |
| ATE161734T1 (de) | 1998-01-15 |
| DK297690D0 (da) | 1990-12-14 |
| JP2933337B2 (ja) | 1999-08-09 |
| EP0427741B1 (en) | 1998-01-07 |
| PT90820B (pt) | 1995-05-31 |
| FI104700B (fi) | 2000-03-31 |
| PT90820A (pt) | 1989-12-29 |
| DE68928533D1 (de) | 1998-02-12 |
| AU630614B2 (en) | 1992-11-05 |
| FI906155A0 (fi) | 1990-12-13 |
| CA1338700C (en) | 1996-11-12 |
| DE68928533T2 (de) | 1998-07-02 |
| KR970010059B1 (ko) | 1997-06-20 |
| DK175805B1 (da) | 2005-03-07 |
| NZ229515A (en) | 1993-02-25 |
| AU3852189A (en) | 1990-01-12 |
| NO905270D0 (no) | 1990-12-06 |
| KR900701328A (ko) | 1990-12-01 |
| WO1989012470A1 (en) | 1989-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5633008A (en) | Method of administering nicotine transdermally | |
| US4908027A (en) | Subsaturated transdermal therapeutic system having improved release characteristics | |
| US5344656A (en) | Subsaturated transdermal therapeutic system having improved release characteristics | |
| US10709669B2 (en) | Microreservoir system based on polysiloxanes and ambiphilic solvents | |
| US5364630A (en) | Subsaturated nicotine transdermal therapeutic system | |
| FI112171B (fi) | Menetelmä transdermaalisiin välineisiin soveltuvien polyisobutyleeniliimojen valmistamiseksi | |
| US5186939A (en) | Laminated composite for transdermal administration of fentanyl | |
| JPH01170476A (ja) | 高度にイオン化した脂肪に不溶な薬物を経皮的に投与する医学用デバイス | |
| KR870003798A (ko) | 생물학적 활성물질을 박동식으로 경피투여하는 의료장치 | |
| KR100603168B1 (ko) | 투명한 경피성 니코틴 전달 장치 | |
| NO302065B1 (no) | Fremgangsmåte til fremstilling av en anordning for transdermal avgivelse av et aktivt middel | |
| KR100624500B1 (ko) | 레리세트론 전달용 경피치료시스템 | |
| AU709288B2 (en) | Transdermal therapeutic system (tts) for the administration of drugs for treatment of drug dependency or drug addiction | |
| US20070202156A1 (en) | Adhesive preparation comprising sufentanil and methods of using same | |
| NL8104929A (nl) | Anticholinergische preparaten, alsmede de bereiding en de toepassing ervan. | |
| JP2003505411A (ja) | カルシウムアンタゴニストを投与するための経皮治療系 | |
| AU682813B2 (en) | Subsaturated transdermal delivery device | |
| US20210290560A1 (en) | Transdermal therapeutic system for dispensing scopolamine without a membrane |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |